$Chidamide plus R‐GDP for relapsed/refractory diffuse large B‐cell lymphoma in patients ineligible for autologous transplantation: A prospective, single‐arm, phase II study$

Chidamide plus R‐GDP for relapsed/refractory diffuse large B‐cell lymphoma in patients ineligible for autologous transplantation: A prospective, single‐arm, phase II study

Abstract Background In relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL), a negative prognosis is frequently linked to heightened epigenetic heterogeneity. Chidamide, a selective histone deacetylase inhibitor, shows promise as a targeted therapy for R/R DLBCL by targeting abnormal epig...

Full description

Saved in:

Bibliographic Details
Main Authors:	Guang‐Liang Chen, Kai Xue, Qunling Zhang, Zu‐guang Xia, Jia Jin, Ran Li, Yizhen Liu, Fangfang Lv, Xiaonan Hong, Xiaoqiu Li, Junning Cao
Format:	Article
Language:	English
Published:	Wiley 2024-08-01
Series:	Cancer Medicine
Subjects:	autologous transplantation chidamide clinical trial diffuse large B‐cell lymphoma epigenetic mechanisms relapsed/refractory
Online Access:	https://doi.org/10.1002/cam4.70142
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Analysis of relapsed/refractory Hodgkin lymphoma treated with autologous transplantation: A single-center experience
by: Vishal Kulkarni, et al.
Published: (2020-01-01)

Chidamide functions as a VISTA/PSGL-1 blocker for cancer immunotherapy
by: Xiaoshuang Niu, et al.
Published: (2025-02-01)

Retrospective study of chidamide-containing regimens as maintenance therapy among T- and NK-cell lymphoma patients
by: Tao Hai, et al.
Published: (2025-03-01)

Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
by: A P Dubey, et al.
Published: (2020-01-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

Venetoclax confers synthetic lethality to chidamide in preclinical models with transformed follicular lymphoma
by: Mengya Zhong, et al.
Published: (2025-05-01)

Is Salvage Autologous Stem Cell Transplantation Still a Viable Treatment Option in Relapsed Myeloma Patients?
by: Luka Čemažar, et al.
Published: (2025-05-01)

The Benefit of Brentuximab Vedotin and Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Single-Center Retrospective Study
by: Diana-Marina FORTOES, et al.
Published: (2025-06-01)

A retrospective study of an irradiation-based conditioning regimen and chidamide maintenance therapy in T-ALL/LBL
by: Xueying Wang, et al.
Published: (2024-12-01)

Chidamide and anlotinib synergistically inhibit high grade B-cell lymphomas via PI3K/AKT signaling pathway
by: Jiazhen Lin, et al.
Published: (2025-08-01)

Mosunetuzumab for relapsed or refractory follicular lymphoma: a case study
by: Ya. V. Krylova, et al.
Published: (2024-09-01)

Treatment of Relapsed and Refractory Hodgkin’s Lymphoma in Children
by: NS Kulichkina, et al.
Published: (2016-01-01)

Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children
by: NA Batmanova, et al.
Published: (2017-07-01)

Efficacy of Anti-CD38 Monoclonal Antibodies for Relapsed or Refractory Multiple Myeloma in Stem Cell Transplant-Ineligible Patients Aged over 65 Years: A Propensity Score-Matched Study
by: Satoshi Yamasaki, et al.
Published: (2024-11-01)

Treatment of pediatric relapsed and refractory acute myeloid leukemia
by: F. A. Makhacheva, et al.
Published: (2023-05-01)

Comparative clinical and economic assessment of polatuzumab vedotin therapy in combination with bendamustine and rituximab for adult transplantation-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma
by: I. N. Dyakov, et al.
Published: (2022-07-01)

Modern approaches to the treatment of relapsed follicular lymphoma
by: Yu. E. Ryabukhina, et al.
Published: (2022-07-01)

Treatment refractoriness and response rates in patients with relapsed/refractory multiple myeloma: a retrospective analysis of real-world data
by: Ning Lyu, et al.
Published: (2025-01-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Updates in novel immunotherapeutic strategies for relapsed/refractory AML
by: Sawyer Bawek, et al.
Published: (2024-12-01)

Combination autologous stem cell transplantation with chimeric antigen receptor T-cell therapy for refractory/relapsed B-cell lymphoma: a single-arm clinical study
by: Danyang Li, et al.
Published: (2025-02-01)

Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial
by: Ya‐Lan Zhou, et al.
Published: (2025-04-01)

The optimal time for autologous hematopoietic progenitor cell transplantation during treatment of Hodgkin's lymphoma. Foreign recommendations and russian experience
by: N. V. Zhukov, et al.
Published: (2014-09-01)

Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group
by: Jiri Minarik, et al.
Published: (2025-04-01)

Response Rate After Modified Regime DHAP and Toxicity with Refractory and Relapsed Disease in Lymphoma Patients
by: Reeta Kumari, et al.
Published: (2023-10-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti‐CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma
by: Yian Zhang, et al.
Published: (2025-08-01)

Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)
by: Josip Batinić, et al.
Published: (2024-11-01)

Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia
by: Hui-Sheng Zhou, et al.
Published: (2025-04-01)

Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center
by: Ziyi Hao, et al.
Published: (2024-12-01)

Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report
by: Yu. E. Ryabukhina, et al.
Published: (2023-12-01)

Refractory/Relapsed Classic Hodgkin Lymphoma Mimicking Disseminated Tuberculosis
by: Mohamed Nazem Alibrahim, et al.
Published: (2025-05-01)

Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen
by: Andrew Whiteley, et al.
Published: (2025-05-01)

Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
by: Barry Paul, et al.
Published: (2025-06-01)

FLAG with Bortezomib in Children and Adolescents with Relapsed/Refractory Acute Myeloid Leukemia in a Resource-Limited Setting: A Single-Center Experience from India
by: Dipesh Dave, et al.

Low Dose Cytarabine and Cladribine for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Clinical Experience
by: SV Gritsaev, et al.
Published: (2016-01-01)

The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy
by: Lingling Yin, et al.
Published: (2025-04-01)

Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma—importance of pre-CAR-T optimization
by: Phoebe Joy Ho, et al.
Published: (2025-08-01)

Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma
by: Shiliang Ge, et al.
Published: (2025-02-01)